Screener
Beam Therapeutics BEAM Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:22 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210338
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Stockholders’ equity: | ||
| Preferred stock, $0.01 par value; 25,000,000 shares authorized, and no shares issued or outstanding at March 31, 2026 and December 31, 2025, respectively | — | — |
| Common stock, $0.01 par value; 250,000,000 shares authorized, 102,741,848 and 101,748,962 issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 1,027 | 1,017 |
| Additional paid-in capital | 2,900,018 | 2,877,449 |
| Accumulated other comprehensive (loss) income | (1,070) | 1,111 |
| Accumulated deficit | (1,735,537) | (1,641,219) |
| Total stockholders’ equity | 1,164,438 | 1,238,358 |
| Total liabilities and stockholders’ equity | $1,480,798 | $1,481,177 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Beam Therapeutics's total equity?
- Beam Therapeutics (BEAM) reported total equity of $1.16B in Q1 2026.
- How has Beam Therapeutics's total equity changed year-over-year?
- Beam Therapeutics's total equity increased by 3.1% year-over-year, from $1.13B to $1.16B.
- What is the long-term trend for Beam Therapeutics's total equity?
- Over 5 years (2020 to 2025), Beam Therapeutics's total equity has grown at a 38.2% compound annual growth rate (CAGR), from $245.56M to $1.24B.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Beam Therapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude